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Many health related problems such as cardiovascular diseases are associated with the formation of
excessive clot in the blood (thrombus). Approaches in cardiovascular disease treatment are preventing the
formation or removing the thrombus. The present thrombolytic agents can be classiﬁed as plasminogen
activators, ﬁbrinolytic enzyme which directly degrades ﬁbrinogen or ﬁbrin and heparin type which act as
thrombin inhibitor. Recently, microbial ﬁbrinolytic enzymes of food origin receive more attention that
leads to escalating efforts to explore traditional fermented foods as the natural sources. We have suc-
cessfully isolated microorganism from Indonesian fermented soybean tofu dregs “Oncom” that secretes
ﬁbrinolytic enzyme. The microorganism identiﬁed as Stenotrophomonas sp. is unique because most of the
reported ﬁbrinolytic microorganism belongs to Bacillus sp. This isolate was found to produce extracellular
ﬁbrinolytic enzyme which could degrade ﬁbrinogen and ﬁbrin directly as determined by ﬁbrinogen
zymography and ﬁbrin plate methods. More importantly, the 30-kD puriﬁed enzymes was found to
demonstrate not onlyﬁbrin and ﬁbrinogen degradation capabilities, but also acted as thrombin inhibitor as
determined using speciﬁc substrates for thrombin. This is the ﬁrst report of a ﬁbrinolytic enzyme that
demonstrates additional synergistic activities. This ﬁnding accentuates the importance of further devel-
opment of the enzyme into a powerful agent to treat the thrombus-related disease effectively.
Copyright © 2017 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A variety of diseases and health problems are inﬂuenced by
reactions that maintain a balance between blood coagulation and
anticoagulation. Coagulation process produces ﬁbrin-containing
blood clots which is formed from ﬁbrinogen by thrombin catalysis
(Lioudaki and Ganotakis 2010; Voet and Voet 1990; Wang et al.
2006). Fibrin can be dissolved by ﬁbrinolytic enzymes such as
plasmin, which is normally activated from the nonactive plasmin-
ogen by a tissue-type plasminogen activator (tPA) (Collen and
Lijnen 2004; Nakajima et al. 1993; Wang et al. 2011). This process
maintains blood ﬂow at vascular injury sites and is an important
component of the normal haemostatic responses. Disturbances inSuhartono).
nian Bogor.
r. Production and hosting by Elsthe anticoagulation process can lead to accumulation of ﬁbrin in the
blood vessels and results as thrombosis conditions which usually
lead to myocardial infarction and other cardiovascular diseases
(Collen and Lijnen 2004; Kim et al. 1996). Researches are continu-
ously pursued to ﬁnd ﬁbrinolytic agents, plasminogen activators
and thrombin inhibitors which are safe and can work efﬁciently.
Tissue plasminogen activator (tPA) is a serine protease which
catalyses the conversion of plasminogen to plasmin, a major
enzyme responsible for breakdown of ﬁbrin in the blood clots.
Plasminogen activators, such as tPA, urokinase, alteplase and
reteplase are used in the clinical medicine to treat embolic and
thrombotic strokes (Dubey et al. 2011; Duffy 2002; deMers 2012).
Thrombin has many important functions in the clotting pathway
leading to formation of the insoluble ﬁbrin clots, so it is a good
target for anticoagulants drugs. Natural antithrombin (AT) is a small
protein molecule of 58 kDa that inactivates several enzymes of the
coagulation system. ATs are required not only for blood disease
disorder, arterial and deep vein thrombosis or coronary syndromes,
but also during sepsis conditions which is known to activate theevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Food Origin Fibrinolytic Enzyme 125coagulation system and induces intravascular ﬁbrin coagulation
associated with increased mortality. Some of the clinically
approved antithrombotic drugs include natural protein AT puriﬁed
from human blood, recombinant human AT, hirudin
peptides anticoagulant heparin and its derivative. Their mode of
actions range from hydrolysing AT or bind at speciﬁc sites of the
thrombin molecules, resulting in the inactivation of the thrombin
action (Fareed et al. 1999; Li et al. 2004).
Microbial ﬁbrinolytic enzymes from food origin attracted much
more medical interest lately. Many indigenous fermented foods
have the ability to prevent thrombosis. A number of potent ﬁbri-
nolytic enzymes have been isolated and characterized from fer-
mented food products, such as Korean Chungkook-Jang (Kim et al.
1996), Japanese Natto (Wang et al. 2009), Chinese Douchi (Wang
et al. 2006) and Indonesian Tempe (fermented soybean; Kim
et al. 2006; Sugimoto et al. 2007). The ﬁbrinolytic enzymes ob-
tained from different microorganisms were mostly of the genus
Bacillus.
We have successfully isolated a microorganism from Indone-
sian fermented soybean/tofu dregs “Oncom” that secretes ﬁbri-
nolytic enzyme. The microorganism was identiﬁed as
Stenotrophomonas sp., which is unique because most of the re-
ported ﬁbrinolytic microorganism belongs to Bacillus sp. We had
conﬁrmed safety of the extracellular protein enzyme of the isolate
11 (Stenotrophomonas sp.) using cell culture and experimental rat;
in addition, the thrombus degrading effect of the enzyme had
been also tested using experimental rats (Nailufar et al. 2016).
This study showed that the puriﬁed extracellular ﬁbrinolytic
enzyme has multiple activities, namely degrading ﬁbrinogen and
ﬁbrin directly as well as acting as AT. This is the ﬁrst report on a
ﬁbrinolytic enzyme that demonstrates additional synergistic ac-
tivities. This ﬁnding accentuates the importance of further
development of the enzyme into a powerful agent to treat the
thrombus-related disease effectively.
2. Materials and Methods
2.1. Microorganisms
Bacterial isolates used as source of ﬁbrinolytic enzymes were
obtained and screened from the red oncom, a fermented soybean/
tofu dregs. Identiﬁcation of the speciﬁc isolate was based on 16s
rDNA gene sequence analysis.
2.2. Fibrinolytic enzyme production
The medium used for cultivation of the bacterial isolate and
enzyme production was described by Miyaji et al. (2005), which
consisted of 0.5% (w/v) casein, 0.5% (w/v) glucose, 0.6% (w/v)
Na2HPO4.2H2O, 0.2% (w/v) yeast extract, 0.1% (w/v) KCl and 0.01%
(w/v) MgSO4.7H2O. pH of the medium was adjusted to 8.1 with
0.1 M sodium carbonate buffer. The cultivation was performed
aerobically in a shaker incubator at 120 rpm for 48 h. The crude
enzyme was obtained as supernatant following centrifugation at
9000g, 4C for 30 min.
2.3. Fibrin plate assay
The ﬁbrinolytic activity was measured using the standard ﬁbrin
plate method (Astrup and Mullertz 1952) with modiﬁcation. In a
petri dish (diameter of 85 mm), 7.3 mL of 0.5% w/v agarose and 200
mL of 1mg/mL bovine thrombinweremixed gently, 2.5mL of 1%w/v
bovine ﬁbrinogen was added and mixed to induce a solid ﬁbrin
formation. The ﬁbrin plate was incubated at 37C after 10 mL of the
enzymesamplewasdroppedonto thedisc (6mm)previouslyplaced
on the surface of the ﬁbrin agar. Diameter of the clearing zone areas
weremeasured, and indicated as ﬁbrinolytic activity of the enzyme.2.4. Fibrin degrading unit
Fibrinolytic activity was measured using ﬁbrin degradation
assay described earlier (Hua et al. 2008). Asmuch as 0.4 mL of 0.72%
ﬁbrinogen was placed in a test tube with 0.1 mL of 245 mM
phosphate buffer (pH 7) and incubated at 37C for 5 min. Then,
0.1 mL of a 20 U/mL thrombin solutionwas added. The solutionwas
incubated at 37C for 10min, 0.1 mL of diluted enzyme solutionwas
added, and incubation was continued at 37C. This solution was
shaked again after 20 and 40 min incubation. At 60 min, as much as
0.7 mL of 0.2 M trichloroacetic acid was added and mixed. The
reaction mixture was centrifuged at 15,000g for 10 min. Then, 1 mL
of the supernatant was collected and the absorbance at 275 nmwas
measured. In this assay, 1 unit (ﬁbrin degradation unit, FU) of
enzyme activity is deﬁned as a 0.01 increase in absorbance at
275 nm/min.
2.5. Protein determination
Protein concentrationwas determined by Lowry's method using
bovine serum albumin as a protein standard (Lowry et al. 1951).
2.6. Ammonium sulphate precipitation
Ammonium sulphate was added to the crude enzyme solution
(free extracellular supernatant) at 4Cwith continuous stirring over
night to get saturation percentage of 65%, then centrifuged at
16,000 g at 4C for 15 min. The precipitate was collected and dis-
solved in a half amount of 0.2 M phosphate buffer pH 7.5 from the
initial volume. The dissolved enzyme was desalted against the
same buffer using HiTrap Desalting column (GE Healthcare Chicago
USA).
2.7. Enzyme puriﬁcation
Protein solution from the desalting process was loaded onto
HiTrap DEAE Sepharose column (GE Healthcare Chicago USA)
equilibrated with 20 mM phosphate buffer, pH 7.5. The columnwas
washed with the same buffer and the proteins were eluted using
the same buffer containing NaCl (0e1.0) M by a stepwise gradient of
0.15 M, 0.35 M, 0.50 M and 1.0 M NaCl at a ﬂow rate of 1 mL/min.
2.8. Thrombin inhibition assay
Chromozym TH (Roche Applied Science Penzberg Germany)
used for thrombin activity assay was dissolved in redistilled water.
The reactionwas performed by adding 2.8 mL of Tris buffer (0.05M,
pH 8.3), 227 mMNaCl and 0.3 mL Chromozym TH (1.9 mM) into the
cuvette. The enzyme sample was added at 0.1 mL, and the absor-
bance at 405 nm was observed. Changes in absorbance: DA/min
was calculated from the linear curve. Under these conditions, the
enzyme activity (U/mL) can be calculated as 3.077  DA/min by
following the instruction manual.
2.9. SDS-PAGE (Sodium Dodecyl Sulphate-Poly Acrylamide Gel
Electrophoresis) and zymogram
SDS-PAGE was performed using Laemmli's method (Laemmli
1970) with 12% separating gel and 4% stacking gel. The gel was
run at 70 V, 400 mA for 2 h. The protein bands were then visualized
by staining the gel with Coomassie blue and the apparent molec-
ular mass of the protein was calculated using low molecular
weight standard protein markers (GE Healthcare).
3. Results
Oncom is a traditional fermented soybean/tofu dregs. The soy
protein soft material used for the basic ingredient comes from the
bean paste left during tofu making, and this made the typical soft
texture in the red oncom. The red colour is due to the metabolism
product of the fungi, indicating high content of beta carotene.
L. Stephani, et al126Indonesian people recognized Oncom as a traditional food rich in
vitamin B and has ability to reduce cholesterol. We used Oncom to
screen for ﬁbrinolytic bacteria and found one of the potent isolates
identiﬁed as Stenotrophomonas sp. The extracellular enzyme was
capable of degrading ﬁbrinogen and ﬁbrin substrates. In our pre-
vious study, we had conﬁrmed safety of the extracellular protein
enzyme produced by this bacterium using cell culture and experi-
mental rat. In addition, the thrombus degrading effect of the
enzyme had been also tested using experimental rats (Nailufar et al.
2016)
3.1. Comparison of ﬁbrinolytic activity
Isolate Stenotrophomonas sp. was grown in the media as
mentioned in the method. The extracellular ﬁbrinolytic enzyme
(ST) was precipitated by 65% ammonium sulphate and dialysed
against phosphate buffer 20 mM, pH 7.5 using HiTrap Desalting
column. The ﬁbrinolytic activity of the bacteria was compared with
the commercial ﬁbrinolytic enzyme, lumbrokinase (LK), a plas-
minogen activator originated from earthworm, which has been
used as medical agents for thrombosis. Both were used at con-
centration 40 mg/mL for the ﬁbrin plate analysis. Fibrinolytic ac-
tivity was shown as clearing zone in the ﬁbrin plate. The result
indicated that ﬁbrinolytic activity from Stenotrophomonas sp. was
comparable with that of the commercial LK (Figure 1).
3.2. Puriﬁcation of ﬁbrinolytic enzyme
Enzyme in the cell-free supernatant (crude) was precipitated by
addition of 65% ammonium sulphate. The pellet was collected,
desalted with HiTrap Desalting column, and washed with 20 mM
phosphate buffer, pH 7.5. The enzyme was then passed through a
DEAE Sepharose column, and washed with 20 mM phosphate
buffer, pH 7.5. The attached proteins were eluted with a stepwise
gradient of 0.15 M, 0.35 M, 0.50 M and 1.0 M of NaCl in the same
buffer at a ﬂow rate of 1 mL/min. Some unbound proteins eluted is
shown as peak I (Figure 2). Peaks II and III were eluted in the
presence of higher NaCl concentrations. All fractions were analysed
using ﬁbrin degrading unit assay and peak III was found to have
ﬁbrinolytic activity. The enzyme was puriﬁed 8.2-fold.Figure 1. Comparison of ﬁbrin-degrading enzyme of extracellular protease from Stenotr
of ﬁbrin degrading enzyme activity was based on the ﬁbrin plate method as described in Figu
activity of the samples. The samples were applied at 40 mg/mL. Extracellular crude enzyme
(LK).3.3. SDS-PAGE analysis
The crude enzyme appeared as ﬁve protein bands in the SDS
PAGE electrogram, with apparent molecular weight of 19e64 kDa.
Peak II was found as 64-kDa protein, peak IIIa as 30-kDa protein,
peak IIIb as 19-kDa protein, whereas peak IV did not show
observable protein band and peak I produced smeared protein
below 20 kDa (Figure 3).3.4. Antithrombin activity
Chromozym TH (Tos-Gly-Pro-Arg-4-nitranilide acetate) was
used as a speciﬁc substrate for assay the thrombin activity. The
capability of thrombin to hydrolyse this substrate was shown as
increase in absorbance at 405 nm (Figure 4). When the crude
enzyme was mixed with thrombin (Figure 4A), the thrombin ac-
tivities were not altered at the time applied. The result was
different when we incubated thrombin with the puriﬁed enzyme
(peak IIIa). Thrombin inhibition was markedly increased after
24 h incubation (Figure 4B). We observed much more signiﬁcant
decrease in the absorbance at 405 nm compared with the absor-
bance shown by thrombin alone. The puriﬁed enzyme (peak IIIa)
itself did not capable of hydrolysing the thrombin substrate. This
implies that the puriﬁed enzyme acted as an inhibitor of thrombin
or behaved as an AT.4. Discussion
Enzyme therapies are becoming more prevalent in the medical
world today, with many manufacturers targeting their advantages
in disease treatment. In the past, the therapeutic use of enzymes
has been largely focused on the use of digestive enzyme. Recently,
however, many newenzymes are reported to havemetabolic effects
and towork directly in concert with the natural metabolic enzymes.
Natural enzymes with ﬁbrinolytic nature has been found potential,
that even could rival pharmaceutical agents in thrombosis treat-
ment and show promises in related areas such as cardiovascular
diseases, stroke, angina, thrombosis, emboli, atherosclerosis,
rheumatism, chronic inﬂammation, hypertension etc.ophomonas sp. (ST) and the commercial product of lumbrokinase (LK). Comparison
re 2. Diameter of the hydrolysed clear zone was measured and calculated as ﬁbrinolytic
from Stenotrophomonas sp. (ST). Commercial ﬁbrinolytic agent from Lumbricus rubellus
Figure 2. Detection of proteins eluted from HiTrap DEAE FF column. Puriﬁcation of ﬁbrinolytic enzyme was performed by anion exchange chromatography (HiTrap DEAE FF column). After precipitation with ammonium sulphate 65%
and dialysis, the protein sample was loaded onto the column, washed with 20 mM phosphate buffer, pH 7.5. The attached proteins were eluted with a stepwise gradient of 0.15 M, 0.35 M, 0.50 M and 1.0 M of NaCl in the same buffer at a
ﬂow rate of 1 mL/min. Unbound eluted protein (peak I). Attached protein eluted by buffer containing 0.15 M NaCl (peak II), 0.35 M (peak IIIa), 0.35 M (peak IIIb), 0.50 M (peak IV) and 1.0 M (peak V).
Food
O
rigin
Fibrinolytic
Enzym
e
127
Figure 3. SDS-PAGE analysis. SDS-PAGE was conducted according to the Laemmli's method (1970). Samples were loaded onto the stacking gel (4%), proteins were resolved in 12%
polyacrylamide gel (resolving gel). Electrophoresis was conducted at 70 V and stained with Coomassie brilliant blue solution. Low molecular weight standard protein markers (GE
Healthcare) were used to predict the molecular weight of the proteins. Bands of unbound protein (peak I) and puriﬁed protein (peaks II, IIIa, IIIb and IV) are shown.
L. Stephani, et al128In this study, the primary target of the enzymatic therapy is the
protein ﬁbrin, which is a ﬁnal product in blood clotting cascade
processes; it is derived from its soluble protein precursor, ﬁbrin-
ogen. Fibrinolytic (thrombolytic) agents for therapy are used to
activate the ﬁbrinolytic system by converting the inactive proen-
zyme, plasminogen into the active enzyme plasmin, that degrades
the ﬁbrin target. The following are the agents available presently
for the clinical use: the physiologic tPA, urokinase-type plasmin-
ogen activator and the bacterial plasminogen activator such as
streptokinase. Despite their widespread use, these agents suffer
from several signiﬁcant limitations, including bleeding complica-
tions. Several lines of research towards improvement of thrombo-
lytic agents are being explored, including search for plasminogen
activators of safer origin. The ﬁnding of a potent ﬁbrinolytic enzyme
Nattokinase from Bacillus natto in the Japanese traditional fer-
mented food Natto known for decades by the Japanese as nutritious
and healthy food has opened up possibilities of safer oral treatment
to overcome thrombosis This ﬁnding has motivated active search-
ing of numerous ﬁbrinolytic microorganisms in the traditional
(Asian) fermented food. These studies revealed that, indeed, food,
especially the fermented food is considered as one of the abundant
sources of ﬁbrinolytic enzymes. Studies of microbes producing
ﬁbrinolytic enzymes from various traditional Asian fermented
foods have also reported that these microorganisms were mostly of
the genus Bacillus (Kim and Choi 2000; Kim et al. 1997; Peng et al.
2003).
In our study, bacteria isolated from red Oncom, a soybean/tofu
dregs fermented product were screened for its ﬁbrinogenolytic and
ﬁbrinolytic activities and three potential isolates were identiﬁed as
Bacillus licheniformis, Bacillus cereus and Stenotrophomonas sp. B.
licheniformis and B. cereus only showed either ﬁbrinogenolytic or
ﬁbrinolytic activity, whereas Stenotrophomonas sp. interestingly
showed both ﬁbrinogenolytic and ﬁbrinolytic activity. An agent
which can degrade both ﬁbrinogen and ﬁbrinwill be more effective
for thrombosis treatment. We had conﬁrmed safety of the extra-
cellular protein enzyme of the isolate Stenotrophomonas sp. using
cell culture and experimental rat; in addition, the thrombus
degrading effect of the enzyme had been also tested using experi-
mental rats (Nailufar et al. 2016). This result encouraged us to
further purify and analyse the enzyme from this isolate. Finding of
food origin ﬁbrinolytic Stenotrophomonas sp. is considered uniqueand surprising because most of the reported ﬁbrinolytic microor-
ganism from fermented food belongs to Bacillus sp.
Genus Stenotrophomonas is not yet well explored, but has been
associated with variety of functions and applications that are
beneﬁcial such as plant growth, bio- and phytoremediation and
generation of useful biomolecules. Stenotrophomonas sp. is known
as an aerobic, non-fermentative, gram-negative bacterium
capable of producing extracellular protease with broad speciﬁc-
ities. The extracellular enzyme can degrade ﬁbrinogen in the
serum component completely, suggesting the potential of appli-
cation in the process of blood clot modiﬁcation (Windhorst et al.
2002). This premise has been demonstrated by the LK from
earthworms Lumbricus rubellus, which is known for its high
ﬁbrinolytic activity (Nakajima et al. 1993). LK, as one of the com-
mercial ﬁbrinolytic agents produced by L. rubellus, was used to
compare its ﬁbrinolytic activity with that of the Stenotrophomonas
sp. enzyme in our study. The result showed that our enzyme had
similar ﬁbrinolytic activity with the commercial LK at similar
concentration applied, which strongly supports the potential
application of ﬁbrinolytic enzyme from this food origin Steno-
trophomonas sp. The similar thrombus degrading effect of our
Stenotrophomonas enzyme and that of LK had been also tested
using experimental rats (Nailufar et al. 2016).
Many blood coagulation and ﬁbrinolytic enzyme/factors are
zymogens of serine proteinase, which hydrolyse speciﬁc peptide
bonds (Devlin 1997). A variety of synthetic substrates are available
for the analysis of activities of these proteins coagulation enzymes.
Thrombin is a serine protease involved in the coagulation
cascade reactions, where it activates various protein factors and
converts the soluble ﬁbrinogen into insoluble strand of ﬁbrin. As
the ﬁnal enzyme in the activation of coagulation system, thrombin
is an important target for the development of new anticoagulant
and/or antithrombotic drugs. This interest has led to ﬁnding of
agents that have either a direct effect on the cleavage site of the
thrombin molecule or can in some other way inhibit its ability to
catalyse the conversion of ﬁbrinogen to ﬁbrin. Direct thrombin
inhibitors are either derived from natural sources, such as hirudin
or are chemically synthesized such as warfarin. Hirudin is a
polypeptide originally obtained from leech. Hirudin acts by irre-
versible binding to the active site of thrombin. With their various
nature and characteristics, thrombin inhibitors are used to
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Figure 4. Reactivity of Chromozym TH to thrombin and thrombin treated with Stenotrophomonas sp. ﬁbrinolytic enzyme. Determination of thrombin activity was conducted
using Chromozym TH substrate. Enzyme was incubated with the crude (A) and puriﬁed enzymes (B) for 0 min, 15 min, 30 min and 24 h before incubation with the chromogenic
substrate. The absorbance was measured for another 12 min as mentioned in the method.
Food Origin Fibrinolytic Enzyme 129prevent arterial and venous thrombosis. They can be used to
prevent and treat deep vein thrombosis, or used as prophylaxis in
atrial ﬁbrillation to avoid thromboembolism (Fareed et al. 1999;
Lee and Ansel 2011).
Thrombin activity may be detected using peptides that contain
the VPR (Valin-Proline-Arginine) recognition sequence such as the
ﬂuorogenic substrates Boc-Val-Pro-Arg-AFC, Boc-Val-Pro-Arg-7-
AMC or chromogenic substrate Boc-Val-Pro-Arg-pNA and Tos-
Gly-Pro-Arg-4-pNA. Synthetic tripeptides (S-2160 and Chromozym
TH) have been used as substrates for the measurement of thrombin
activity. Using Chromozym TH (Tos-Gly-Pro-Arg-4-nitranilide ace-
tate) which will release p-nitroanilide is qualiﬁed for assessing
anti-thrombin activity (Devlin 1997). The puriﬁed enzyme of
Stenotrophomonas showed inhibition of thrombin activity by 50% at
24 h incubation time. Discovery of new AT is still limited and thusinterested to study. AT agents are also important for the treatment
of patients with hereditary AT III deﬁciency in connection with
surgical or obstetrical procedures or when the patients suffer from
thromboembolism.
The puriﬁed Stenotrophomonas enzyme capable of hydro-
lysing ﬁbrin and ﬁbrinogen, as well as possessing anti-thrombin
activity is a protein of approximately 31 kD. The molecular size is
similar to that of BSN1 ﬁbrinolytic protease from B. subtilis
TKU007 (30 kD; Wang et al. 2011) and B. subtilis BK-17 (31 kD;
Jeong et al. 2001). Fibrinolytic enzymes of different sizes from
various microorganisms have been reported: 47 kD for strepto-
kinase, 28 kD for nattokinase (Dubey et al. 2011), 28.2 kD for
enzyme from Bacillus sp. strain CK11-4 (Kim et al. 1996) and 27.5
kD for enzyme from B. subtilis TP-6, isolated from Tempe (Kim
et al. 2006).
Fibrinogen 
Thrombin 
Result : 
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Figure 5. Fibrinolytic enzyme ST: possible mechanism of action in dissolving
ﬁbrin. Dotted arrow indicates hydrolysis mechanism, whereas ﬂat arrow indicates
the activation mechanism. Extracellular enzyme produced by Stenotrophomonas sp.
(ST) isolated from Indonesian fermented food, Oncom can degrade ﬁbrinogen and
ﬁbrin directly, whereas the puriﬁed enzyme of ST showed additional thrombin
inhibiting activity.
L. Stephani, et al130In conclusion, we have shown ﬁbrin and ﬁbrinogen degrading
activity of enzyme from Stenotrophomonas sp. isolated from Indo-
nesian traditional fermented food Oncom. The puriﬁed enzymewas
also found as an inhibitor of thrombin activity. This ﬁnding high-
lights the multiple actions of Stenotrophomonas enzyme. As an
illustration, potential mode of action of Stenotrophomonas enzyme
in ﬁbrinolysis is presented in Figure 5.
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